Famous fund managers' second-quarter portfolio adjustments revealed: increasing positions in military industry, with divergences in the pharmaceutical sector

Recently, with some listed companies disclosing their top ten circulating shareholders, the repositioning trends of certain well-known fund managers in the first half of the year have been revealed. Journalists have found that there are still divergences among fund managers regarding pharmaceutical stocks. For example, in the second quarter, while Dongfang Biotech, which was heavily increased by Wan Minyuan, saw some fund managers choose to reduce their holdings; on the other hand, Mabwell, which Jin Xiaofei has held for a long time, was reduced by Lu Bin. Interviewees pointed out that the market's divergence on the pharmaceutical sector mainly focuses on valuation versus performance realization, risks and returns of innovative drug development, market sentiment and capital flow, policy impacts, and short-term volatility. In addition, recently, public funds have shown increased attention to the military industry sector. Some institutions have warned that the trading in the military sector is heating up, and caution is needed regarding short-term volatility risks